Evaluating Whole Foods Supplementation on Cognition

Exclusion Criteria

• •A cognitive deficit greater than that indicated according to the MMSE score
• •A clinical diagnosis of AD and/or related disorders
• •A psychiatric diagnosis of schizophrenia, other psychotic disorders, bipolar disorder, major depression with psychotic features, delirium, and alcohol or substance abuse/dependence
• •Bleeding disorders
• •Aphasia or sensory, motor, and/or visual disturbances that would have interfered with psychometric tests
• •Gastrointestinal disorders causing impaired absorption of the study supplements
• •Insulin-dependent diabetes
• •Major conditions such as cardiovascular, pulmonary, renal, thyroid, hepatic, gastrointestinal, or seizure
• •Hematologic or oncologic disorders treated with chemotherapy in the previous two years
• •Active chemotherapy or radiation treatment for cancer
• •Current cigarette smoking
• •More than three major medical or psychiatric hospitalizations in the past year
• •Diagnosis of a terminal illness
• •A T score \> 70 on the Global Severity Index of the Brief Symptoms Inventory (BSI)
• •A score ≥ 29 on the Beck Depression Inventory-II (BDI) (15)
• •Prescription and OTC sympathomimetic amines and antihistamines within 2 days of an assessment visit
• •Cognition enhancing drugs consumption such as Donepezil, Rivastigmine, Galantamine, and Tacrine
• •Coumadin, tricyclic antidepressants, antipsychotics, and anticonvulsants
• •Cognition-enhancing supplements, herbs, or antioxidants that could not be stopped during the trial
• •Participating in a concurrent trial for drugs, supplements, or treatment that affects behavior or cognitive function